Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
With
Gynecologic Oncology Group
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed recurrent or persistent disease ovarian epithelial or primary peritoneal cancer
Measurable disease
Must have received 1 prior platinum-based (carboplatin, cisplatin, or another organoplatinum compound) chemotherapy regimen for primary disease. Patients who had not received prior paclitaxel may have received a second regimen that included paclitaxel
Treatment-free interval \< 6 months after prior platinum-based therapy OR progressed during platinum-based therapy
You may not be if
Patients who have had prior therapy with pemetrexed
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
Patients who have received radiation to more than 25% of marrow
